CMV ICP36 antibody

Principal name

CMV ICP36 antibody

Alternative names for CMV ICP36 antibody

HHV5, HCMV, UL44, Cytomegalovirus, DNA polymerase processivity factor, Polymerase accessory protein

SwissProt ID

P16790 (Hcmva)

Gene ID

1487805

Available hosts

Mouse

Available applications

Western blot / Immunoblot (WB), Immunocytochemistry/Immunofluorescence (ICC/IF), Enzyme Immunoassay (E)

Background of CMV ICP36 antibody

Human Cytomegalovirus is a herpesvirus of  the betaherpesvirinae subfamily. The members of this subfamily tend to have a restricted host range, slow spread in cell culture and a long growth cycle as compared to Herpes Simplex Virus. CMV infected cells may become enlarged (cytomegalia), showing intranuclear inclusions. Co-survival of cell and virus is often established. Two recently recognized herpes viruses, HHV-6 and HHV-7, also belong to the betaherpesvirinae subfamily.

The virus is found universally throughout all geographic locations and socioeconomic groups and infects between 50 and 85% of adults in the United States by 40 years of age. CMV is also the virus most transmitted to a developing child before birth. The infection is more widespread in developing countries and in areas of lower socioeconomic conditions. For most healthy people who acquire the virus after birth, there are few symptoms and no long-term health consequences. Symptomatic experiences can include a mononucleosis-like syndrome with prolonged fever and a mild hepatitis. Once a person becomes infected, the virus remains viable but usually dormant in that person for life. For the vast majority of people, CMV infections are not a serious problem.

CMV infection is problematic to certain high-risk groups. These groups include (1) the unborn child (neonate) (2) people who work with children and (3) the immunocompromised, such as organ transplant patients and those infected with the human immunodeficiency virus (HIV). Neonates, infected in utero, may present with rashes, hepatitis, gastroenteritis and a range of organ specific maladies. With supportive treatment, most survive. However, in the first few years of life, 80-90% of the survivors will experience complications that may include hearing loss, vision impairment and varying degrees of mental retardation. CMV has also been associated with retinitis and increased mortality in patient groups undergoing immunosuppression due to organ transplant treatment or HIV infection.

General readings

J. Virology (1995), 69(4):2047

5 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

CMV ICP36 antibody

CMV ICP36 Mouse IgG1 10D8 Aff - Purified E, ICC/IF, WB
1 mg / €1,520.00
  Virusys Corporation

CMV ICP36 antibody

CMV ICP36 Mouse IgG1 10D8 Aff - Purified E, ICC/IF, WB
0.1 mg / €360.00
  Virusys Corporation

CMV ICP36 antibody

CMV ICP36 Mouse IgG1 CH13 Aff - Purified ICC/IF, WB
0.5 mg / €560.00
  Virusys Corporation

CMV ICP36 antibody

CMV ICP36 Mouse IgG2b CH16 Aff - Purified ICC/IF, WB
0.5 mg / €560.00
  Virusys Corporation

Proteins & Growth Factors

Catalog No. Species Pres. Purity Source  

CMV ICP36

CMV ICP36 Purified >95% pure (10% PAGE, coomassie staining). Sepharose purification E. coli
1 mg / €1,170.00
  Acris Antibodies GmbH

5 Item(s)

per page
  • LinkedIn